Research
Hormonal
Lactobacillus sp. supplementation significantly decreases leptin levels and increases adiponectin levels in non-comorbid obese individuals.
Lactobacillus supplementation may help improve your hormonal profile by lowering leptin (which can promote fat storage) and raising adiponectin (which improves insulin sensitivity and fat burning). This hormonal shift supports weight management efforts.
ModerateSupportsMEDIUM confidence
Leptin levels significantly decreased (MD: -2.11 μg/mL; 95%CI: -3.59–(-0.64), p=0.005) compared to before Lactobacillus sp. supplementation, while adiponectin levels increased (MD: 0.71 μg/mL; 95%CI: 0.22–1.20, p=0.004) following Lactobacillus sp. supplementation compared to placebo group.
Why this rating
Moderate quality evidence per GRADE assessment.
Source
Probiotic Lactobacillus sp. as a strategy for modulation of non-comorbid obesity: A systematic meta-analysis and GRADE assessment of randomized controlled trials
Juan Alessandro Jeremis Maruli Nura Lele et al. · Narra J · 2025
DOI 10.52225/narra.v5i2.1562
Meta-analysis · 12 studiesCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lactobacillus sp. probiotic supplementation significantly reduces body mass index, body weight, waist and hip circumference, and visceral/subcutaneous fat mass in non-comorbid obese individuals compared to placebo.Good
- Lactobacillus sp. supplementation is safe and well-tolerated in non-comorbid obese individuals, with no significant adverse events reported.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →